Seattle Genetics Inc [SGEN]
$79.20 2.49 (3.25%)
Market Cap 12.81 Billion
Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.
EPS -0.49 P/E Ratio 0.00
Previous Earnings Thu, Apr 25, 2019
Pay Date --
|Symbol||Price||Day %||YTD %|
This list of trending stocks may change throughout the trading day.